ProCE Banner Activity

Future Directions in Combination Immunotherapy Strategies for Metastatic Triple-Negative Breast Cancer

Clinical Thought
Are you aware of new strategies using combination immunotherapy in the treatment of metastatic TNBC? Read my thoughts on this promising approach to potentially improve response to immunotherapy in these patients.

Released: April 27, 2020

Expiration: April 26, 2021

No longer available for credit.

Share

Faculty

David B. Page

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

David B. Page, MD, has disclosed that he has received consulting fees from Brooklyn ImmunoTherapeutics and Genentech; funds for research support from Bristol-Myers Squibb, Brooklyn ImmunoTherapeutics, and Merck; and fees for non-CME/CE services from Genentech and Novartis.